Copyright 2005 ESPICOM Business Intelligence Ltd.
All Rights Reserved
Drug Delivery Insight
Dermisonics is developing a major new commercial application of its proprietary U-Strip drug-delivery platform, called the Antiseptic Wand, or A-Wand. This device could present a shift in improved healthcare and infection control capabilities in the antiseptics market, and has already generated customer interest in major industries. The A-Wand is an advanced, proprietary ultrasonic hand-held instrument designed to have multiple uses for consumers, the medical industry, EMS first responders, emergency room personnel and the military. It is designed for the greatly improved application of antiseptic solutions to cuts, abrasions and wounds. It can be used before applying band-aids at home, for example, or else before the closing of a wound in surgery. The A-Wand comes with a replaceable Patch-Cap that holds up to 40mL of antiseptic cream, and uses alternating ultrasonic waveforms to enlarge the diameter of the skin’s pores, enabling antiseptics to permeate the skin (stratum corneum) into the dermis through the sweat pores. The device’s ultrasonic substance delivery technology inventor, Dermisonics’ Executive Vice President Bruce Redding, believes that this device adds a new dimension to the multibillion dollar wound care field. The A-Wand patent pending technology will represent the company’s 12th patent application based on the original “Substance Delivery Device,” which was issued in June.